+

WO1998047497A3 - Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire - Google Patents

Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire Download PDF

Info

Publication number
WO1998047497A3
WO1998047497A3 PCT/US1998/008164 US9808164W WO9847497A3 WO 1998047497 A3 WO1998047497 A3 WO 1998047497A3 US 9808164 W US9808164 W US 9808164W WO 9847497 A3 WO9847497 A3 WO 9847497A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
compositions
treatment
methods
infections
Prior art date
Application number
PCT/US1998/008164
Other languages
English (en)
Other versions
WO1998047497A2 (fr
Inventor
Thomas E Fleming
Herbert C Mansmann Jr
Original Assignee
Fleming & Company Pharmaceutic
Thomas E Fleming
Herbert C Mansmann Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/844,909 external-priority patent/US5939394A/en
Priority claimed from US08/844,988 external-priority patent/US5922765A/en
Application filed by Fleming & Company Pharmaceutic, Thomas E Fleming, Herbert C Mansmann Jr filed Critical Fleming & Company Pharmaceutic
Priority to AU71505/98A priority Critical patent/AU7150598A/en
Publication of WO1998047497A2 publication Critical patent/WO1998047497A2/fr
Publication of WO1998047497A3 publication Critical patent/WO1998047497A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention a trait à des compositions et aux méthodes afférentes aux fins de la prévention et/ou du traitement d'affections allergiques, de maladies auto-immunes, de chocs septiques ou de maladies infectieuses. Il est utilisé, dans le cadre de ces méthodes, du gluconate de magnésium seul ou associé à un ou plusieurs antioxydants ou à un agent anti-inflammatoire. Cette invention concerne également l'inhibition de la production de quantités inopportunes de médiateurs des lipides et de cytokines.
PCT/US1998/008164 1997-04-23 1998-04-23 Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire WO1998047497A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71505/98A AU7150598A (en) 1997-04-23 1998-04-23 Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/844,909 US5939394A (en) 1996-01-18 1997-04-23 Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
US08/844,988 US5922765A (en) 1996-01-18 1997-04-23 Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength
US08/844,909 1997-04-23

Publications (2)

Publication Number Publication Date
WO1998047497A2 WO1998047497A2 (fr) 1998-10-29
WO1998047497A3 true WO1998047497A3 (fr) 1999-01-21

Family

ID=27126538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008164 WO1998047497A2 (fr) 1997-04-23 1998-04-23 Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire

Country Status (1)

Country Link
WO (1) WO1998047497A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
DE10349115A1 (de) * 2003-10-22 2005-06-16 Biosyn Arzneimittel Gmbh Kombinationspräparat zur Behandlung der Sepsis
WO2014022886A1 (fr) 2012-08-08 2014-02-13 Fischer Karen Jane Procédé, utilisation et composition de complément alimentaire pour au moins traiter un trouble atopique ou non-atopique chez un patient

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307382A1 (de) * 1983-03-02 1984-09-06 Hans-Peter 8022 Grünwald Walter Arzneimittel, geeignet zur behandlung von entzuendlichen veraenderungen der bronchialschleimhaut
DE3517916A1 (de) * 1985-05-18 1986-11-20 Krüger GmbH & Co KG, 5060 Bergisch Gladbach Vitamin-e-brausetabletten
US5002780A (en) * 1987-07-31 1991-03-26 Caola Kozmetikai Es Haztartasvegyipari Vallalat Magnesium salt of a fatty acid acyl lactylate
FR2688133A1 (fr) * 1992-03-06 1993-09-10 Plantes Tropicales Lab Composition d'hygiene a base d'eau de mer.
CH684630A5 (fr) * 1992-08-21 1994-11-15 Danielle Girardet Composition pharmaceutique à base d'oligo-éléments.
WO1995028937A1 (fr) * 1994-04-20 1995-11-02 Béres Export-Import Rt. Concentre aqueux et son procede de preparation
EP0705542A1 (fr) * 1994-09-21 1996-04-10 Sandoz Nutrition Ltd. Composition diététique destinée à des adolescents
WO1996019182A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
EP0739629A1 (fr) * 1995-04-28 1996-10-30 Ravi Shrivastava Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques
WO1997025959A2 (fr) * 1996-01-18 1997-07-24 Fleming & Company, Pharmaceuticals Compositions et procedes s'appliquant a la prevention et au traitement de l'atherosclerose et des lesions consecutives a des perfusions au moyen de sels de magnesium
WO1997026894A1 (fr) * 1996-01-25 1997-07-31 Weglicki William B Gluconate de magnesium intraveineux pour le traitement d'etats causes par un stress oxydant imputable a la repartition des radicaux libres
US5681554A (en) * 1995-06-28 1997-10-28 Cosmair, Inc. Composition for treating hair and method for using the same

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307382A1 (de) * 1983-03-02 1984-09-06 Hans-Peter 8022 Grünwald Walter Arzneimittel, geeignet zur behandlung von entzuendlichen veraenderungen der bronchialschleimhaut
DE3517916A1 (de) * 1985-05-18 1986-11-20 Krüger GmbH & Co KG, 5060 Bergisch Gladbach Vitamin-e-brausetabletten
US5002780A (en) * 1987-07-31 1991-03-26 Caola Kozmetikai Es Haztartasvegyipari Vallalat Magnesium salt of a fatty acid acyl lactylate
FR2688133A1 (fr) * 1992-03-06 1993-09-10 Plantes Tropicales Lab Composition d'hygiene a base d'eau de mer.
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
CH684630A5 (fr) * 1992-08-21 1994-11-15 Danielle Girardet Composition pharmaceutique à base d'oligo-éléments.
WO1995028937A1 (fr) * 1994-04-20 1995-11-02 Béres Export-Import Rt. Concentre aqueux et son procede de preparation
EP0705542A1 (fr) * 1994-09-21 1996-04-10 Sandoz Nutrition Ltd. Composition diététique destinée à des adolescents
WO1996019182A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
EP0739629A1 (fr) * 1995-04-28 1996-10-30 Ravi Shrivastava Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques
US5681554A (en) * 1995-06-28 1997-10-28 Cosmair, Inc. Composition for treating hair and method for using the same
WO1997025959A2 (fr) * 1996-01-18 1997-07-24 Fleming & Company, Pharmaceuticals Compositions et procedes s'appliquant a la prevention et au traitement de l'atherosclerose et des lesions consecutives a des perfusions au moyen de sels de magnesium
WO1997026894A1 (fr) * 1996-01-25 1997-07-31 Weglicki William B Gluconate de magnesium intraveineux pour le traitement d'etats causes par un stress oxydant imputable a la repartition des radicaux libres

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERKOW: "MERCK MANUAL OF DIAGNOSIS AND THERAPY", 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J., XP002080013, 14658 *
MANSMANN H C JR: "Manifestation of concurrent intracellular magnesium deficiency in symptomatic allergic patients.", SMETANA, R. (ED.). ADVANCES IN MAGNESIUM RESEARCH, 1. MAGNESIUM IN CARDIOLOGY;FIFTH EUROPEAN MAGNESIUM CONGRESS, VIENNA, AUSTRIA, 1995. XIII+617P. JOHN LIBBEY AND CO. LTD.: LONDON, ENGLAND, UK. 0 (0). 1997. 308-312. ISBN: 0-86196-555-8, XP002080011 *
SARMA P.C. ET AL: "Therapeutic uses of magnesium.", INDIAN JOURNAL OF PHARMACOLOGY, (1995) 27/1 (7-13). ISSN: 0253-7613 CODEN: INJPD2, India, XP002080012 *

Also Published As

Publication number Publication date
WO1998047497A2 (fr) 1998-10-29

Similar Documents

Publication Publication Date Title
EP2123665A3 (fr) Inhibiteurs de l'enzyme de conversion d'interleukine-1$g(b)
CA2289851A1 (fr) Composes et methodes d'inhibition de l'expression de vcam-1
EP1018517A3 (fr) Agents liants au CD23 pour le traitement des maladies inflammatoires, autoimmunes ou allergiques
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
CA2362816A1 (fr) Compositions de valdecoxib
WO2003034984A9 (fr) Compositions et procedes pour le diagnostic et le traitement d'affections intestinales inflammatoires
EP1762557A3 (fr) Mediateurs lipidiques actives par l'aspirine
AU2002256093A1 (en) Bulking agents as satiety agents
EP1389465A3 (fr) Utilisation d'un extrait de feuilles de Olea Europaea comme agent antiradicalaire
EP2060255A3 (fr) Procédés et compositions pour la prévention et le traitement de maladie inflammatoire, maladie auto-immune, et rejet d'implant
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
EP1443935A4 (fr) Traitement d'une maladie infectieuse a l'aide d'inhibiteurs de la famille ced-3/ice (enzyme de conversion de l'interleukine-1 beta)
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
BR0311254A (pt) Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino
CA2320388A1 (fr) Nouveaux derives d'acide dihydroxyhexanoique
CA2192480A1 (fr) Benzopyrannes et leur utilisation en tant qu'agents therapeutiques
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
WO1998047497A3 (fr) Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire
WO1998005777A3 (fr) BCL-xη, UNE NOUVELLE ISOFORME DE BCL-x, ET UTILISATIONS ASSOCIEES
WO2002030888A3 (fr) Composes tricycliques et leurs utilisations
AU5006499A (en) Compositions and methods for the treatment or prevention of pulmonary infections
WO2003093242A3 (fr) Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
MXPA03004450A (es) Compuestos triciclicos y sus usos.
CA2534303A1 (fr) Composes de nitrone aryle bicycliques et heteroaromatiques, promedicaments et compositions pharmaceutiques de ces composes, destines a traiter des troubles chez les humains

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546329

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载